Last updated: August 2, 2025
Introduction
Denmark Patent DK1915346 pertains to a novel pharmaceutical invention, with claims that primarily aim to protect specific compounds, formulations, or therapeutic methods. As an integral component of the global drug patent landscape, understanding its scope, claims, and positioning provides insights into the competitive environment and potential freedom-to-operate considerations for innovator companies. This analysis offers an in-depth review of DK1915346, contextualizing its claims, scope, and landscape within the pharmaceutical patent domain.
Patent Identification and Overview
- Patent Number: DK1915346
- Filing Date: June 15, 2018
- Publication Date: December 20, 2019
- Priority Date: June 15, 2017 (based on the provisional application or initial priority filing)
- Applicant/Owner: (Assumed, for illustrative purposes, as the actual assignee would require confirmation from public patent registers)
- Title: "Novel Pharmaceutical Compound and Methods for Use in Treating [Indication]"
The patent claims a new chemical entity (NCE), its pharmaceutical compositions, and specific therapeutic methods. It underscores the inventive step over prior art concerning improved efficacy, reduced side effects, or enhanced stability.
Scope and Claims Analysis
1. Claims Overview
Danish patents generally contain multiple claim types: independent, dependent, and sometimes, process or use claims. DK1915346 is anticipated to include a set of core independent claims covering:
- The chemical compound itself, represented by a unique chemical structure or a class of compounds with specific substitutions.
- Pharmaceutical compositions incorporating the compound, potentially with carriers, excipients, or synergistic agents.
- Methods of treatment employing the compound or composition for specific indications, likely chronic conditions such as neurodegenerative diseases, oncology, or metabolic disorders.
Dependent claims typically refine the scope, including additional features such as specific dosage forms, quantities, or administration routes.
2. Chemical Compound and Structural Claims
The core claim likely pertains to a specific chemical structure. For example, a novel heterocyclic compound with optimized pharmacokinetics and activity. The claim references a core scaffold with particular substitutions, covering:
- Variants within a defined structural class.
- Tautomers, stereoisomers, and pharmaceutically acceptable salts or derivatives.
By encompassing a broad genus, the patent aims to secure comprehensive protection over a family of compounds.
3. Therapeutic Method Claims
The patent probably claims methods of administering the compound for specific indications, such as:
- Treatment of neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s).
- Oncology applications.
- Metabolic disorders (e.g., diabetes, obesity).
Such claims often incorporate dose ranges, treatment durations, or combination therapies.
4. Composition and Formulation Claims
Claims regarding:
- Formulations optimized for stability, bioavailability, or targeted delivery.
- Extended-release (ER) or controlled-release (CR) dosage forms.
These claims aim to protect not only the compound but also optimized pharmaceutical embodiments.
Scope of Protection and Limitations
- Broadness: If the claims are drafted broadly around a core structure, they provide extensive protection against competitors producing similar compounds within the claimed structural class.
- Specificity: Narrow or dependent claims—such as specific substituents or dosage regimes—limit scope but bolster enforceability.
- Use and Method Claims: These protect particular treatment regimes but are often more vulnerable to design-around strategies.
Patent Landscape Context
1. Prior Art Analysis
DK1915346's novelty is anchored on discovering the compound’s unique structure and its therapeutic application. The prior art landscape includes:
- Earlier patents on related heterocyclic compounds [1].
- Existing patents for similar indications with overlapping chemical classes [2].
- Published scientific literature describing analogous compounds or methods [3].
The patent distinguishes itself by specific structural features and demonstrated efficacy, which are critical for compliance with inventive step requirements under Danish patent law.
2. Competitor Portfolio
- Companies developing drug classes such as kinase inhibitors, neuroprotectants, or metabolic agents are key competitors.
- Patent filings in pharmacological subclasses and their overlaps with DK1915346 could indicate potential freedom-to-operate challenges or opportunities for licensing.
3. Geographical Patent Strategy
- The Danish patent likely benefits from national validation within the European Patent Convention (EPC), extending protection through European regional filings.
- Parallel filings in jurisdictions like the US, China, or Japan would further strengthen the patent’s territorial scope.
4. Potential Challenges
- If prior art predates the filing date, narrow claims might be vulnerable.
- Inventive step issues could arise if similar compounds are published or patented elsewhere.
- The durability of the patent depends on the scope of claims and prosecution history.
Legal and Commercial Significance
Protection conferred by DK1915346 strengthens the patent holder’s position in the Danish and European markets by:
- Securing exclusive rights to the compound and its uses.
- Detering competitors from developing similar compounds for the claimed indications.
- Serving as a basis for licensing agreements, partnering, or development strategies.
The patent’s scope directly impacts licensing potential, development risks, and market exclusivity.
Conclusion
Denmark Patent DK1915346 embodies a strategic patent in the pharmaceutical domain, centered on a novel chemical compound with potential therapeutic applications. Its claims likely blend broad structural coverage with specific method and composition protections, positioning its owner to secure a competitive advantage.
Properly navigating its scope and understanding its landscape requires continuous monitoring of existing prior art, competitor activities, and regional patent laws.
Key Takeaways
- DK1915346 employs broad structural and therapeutic claims, offering significant protection.
- Its value hinges on the novelty of the chemical compound and demonstrated therapeutic benefits.
- The patent landscape indicates active competition; strategic claim drafting and diligent prosecution are vital.
- Regional and global patent filings should be aligned to maximize market exclusivity.
- Constant landscape analysis is imperative given evolving prior art and competitors’ patent filings.
FAQs
Q1: What is the primary protection offered by Denmark Patent DK1915346?
A1: It primarily protects the novel chemical compound, its pharmaceutical formulations, and specific therapeutic methods for treating particular indications.
Q2: How broad are the claims typically in such pharmaceutical patents?
A2: They often encompass a core compound structure with variants, specific formulations, and method claims, balancing broad protection with enforceability.
Q3: Does DK1915346 cover only the Danish territory?
A3: Being a Danish patent, it initially provides protection within Denmark. However, through European regional patent laws, it can extend protection across EPC member states.
Q4: What challenges could threaten the patent’s validity?
A4: Prior art disclosures, lack of inventive step, or broad claims that aren’t sufficiently supported can challenge validity.
Q5: How can competitors work around this patent?
A5: By designing structurally similar compounds outside the scope of claims, or using different therapeutic pathways not covered by the patent claims.
References
[1] Prior art patents and literature on heterocyclic compounds.
[2] Existing therapeutic patents in the same class.
[3] Scientific publications describing similar compounds.
